An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Decitabine improves patient outcomes in myelodysplastic syndromes

Hagop M. Kantarjian, Jean‐Pierre J. Issa, C Rosenfeld et al. · Cancer · 2006 · 1.5K citations

Medicine, Hematology, Pharmacology +14

Aberrant CpG-island methylation has non-random and tumour-type–specific patterns

J Costello, Michael C. Frühwald, Dominic J. Smiraglia et al. · Nature Genetics · 2000 · 1.4K citations

Life Sciences, Genetics, Molecular Biology +14

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies

Jean‐Pierre J. Issa, Guillermo Garcia‐Manero, Francis J. Giles et al. · Blood · 2003 · 817 citations

Medicine, Oncology, Pharmacology +14

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Bruce D. Cheson, John M. Bennett, Hagop M. Kantarjian et al. · PubMed · 2000 · 665 citations

Medicine, Hematology, Internal Medicine +11